ArcovaarcovaResources
Sign inStart for free
Resources/Timing outreach with readiness
Resources

Timing Outreach With Readiness Signals: When to Reach Out, Not Just Who

Good-fit accounts sit quiet for months, then something changes. That is the moment to reach out. The cues to move are concrete: new budget, a hire into a role you sell into, or a new problem to solve. The goal is not more outreach, it is outreach timed to when something actually happened.

8 min readUpdated Jul 8, 2026

Key takeaways

  • Good-fit accounts sit quiet for months, then something changes. That's the moment to reach out.
  • The cues to move: new budget, a hire in a role you sell into, or a new problem to solve.
  • Signals don't all stay useful for the same length of time. A demo request needs a same-day reply, while a funding round signal may still be live weeks later.

Fit tells you who to target. It does not tell you when. Reach out at the wrong moment on a genuinely good-fit account and you get a polite non-response, and a warm account cools off for no good reason.

Fit tells you who; readiness tells you when

Readiness is what separates "a company we should eventually sell to" from "something just happened that makes this month a better time to reach out than last month." It is built from public events, each one pointing at a concrete change inside the account.

The cues that mean it's time

A readiness signal is really one of a few concrete changes. Whether it is a funding round, a hire, an FDA milestone, or a conference booking, each one points at one of these:

New budget

Money to spend just showed up: a funding round, a grant, a milestone payment. The clearest sign a purchase is even possible.

A new problem to solve

Work just got more complex: a trial moving to the next phase, an FDA milestone, a new or expanding facility. A real problem now exists that you might be the one to solve.

A new decision-maker

A new buyer or team is in place: a relevant hire, a promotion, a contact who just changed roles or companies. New people usually means existing vendor relationships are back up for review.

A shift in strategy

The company’s direction or program mix just changed: a licensing deal, a co-development agreement, a move toward commercial launch. Priorities are moving.

Why timing beats persistence

A good-fit account with nothing happening is not a "no," it is a "not yet." The instinct on a strong account that has gone quiet is to reach out anyway, on a schedule, because it feels productive. In practice that produces a string of low-response messages and can wear out a relationship that would have answered well once a real reason to talk appeared. The better default is to keep the account on a watch list and move the moment a real signal shows up.

Signals decay, and not all at the same rate

A signal's relevance fades over time, but how fast depends heavily on what kind of event it is:

  • First-party, high-urgency signals such as a demo request or an inbound enquiry are the most time-sensitive of all; responding as close to same-day as possible matters far more here than for any other signal type.
  • Hiring and role-change signals, like a new hire, a promotion, or a job change, tend to stay strongest in the first one to a few months after the event, while the new person or team is still settling in and forming opinions about vendors.
  • Funding and major strategy signals, like a raise, a licensing deal, or an M&A event, tend to persist much longer, often most of a year, because the resulting budget or strategic shift plays out over an extended period rather than a single moment.
  • Clinical and regulatory milestones, like a phase transition or an FDA approval, are usually strongest right around the milestone itself and in the months that follow, then gradually lose relevance as the program moves on to its next stage.
  • Visibility and research signals, like a conference appearance or a publication, have the shortest useful shelf life, typically a few weeks, since their value is mostly in giving an outreach message a timely, specific hook.

The takeaway: how long you can wait depends on the signal type, not one blanket rule like "anything older than X days is stale."

Signals compound

Confidence goes up when several of these cues land together on the same account, because it usually means a real, company-wide shift rather than a one-off: budget arriving alongside a new need, or a strategy change bringing in new people.

See which signals actually matter in biotech and pharma for the full catalog these cues are built from.

A simple rule for cadence

In practice the rule is simple: move quickly once a real signal lands on a good-fit account, and resist the urge to manufacture activity on accounts that have not moved.

Where Arcova fits: Arcova reads the underlying life science signals into these cues automatically for every fit-qualified account, and only flags "reach out" when a real event is behind it. Otherwise a strong-fit account stays on a watch list instead of quietly dropping out of view.
Free preview

See it on your own company

Enter your company domain and Arcova maps your market and target buyers free. No login, about a minute.

Try it free →
Free preview

See it on your own company

Enter your company domain and Arcova maps your market and target buyers free. No login, about a minute.

Try it free →

Frequently asked questions

What if a great-fit account never shows a readiness signal?

It stays a good account on your monitor list, not a lead to force. Not every account will show a public signal on a predictable schedule, and pushing outreach on a good-fit account with no real trigger tends to produce weak reply rates and can burn a relationship you would rather keep warm for when a real signal does appear.

What if several signals land on the same account at once?

That is the strongest case to reach out. A funding round alongside a new hire alongside a phase transition usually means a real, company-wide change rather than a one-off event, so a message that ties them together tends to land better than one built on a single data point.

Does the day or time I send a message matter as much as the underlying signal?

Less than the signal does. General email-timing advice (weekday mornings, avoiding Monday and Friday) is a reasonable tiebreaker, but it is a small effect next to whether the message is landing during a real window of relevance. A well-timed message off a real signal, sent on a mediocre day, will still outperform a generic message sent at the statistically optimal hour with nothing behind it.

How quickly after a signal appears should the message actually go out?

As close to immediately as your process allows, for the highest-urgency signal types. A first-party signal like a demo request loses relevance within a day or two; a funding round or a phase transition stays live for months, so a few days of lag barely matters. The general rule: match your response speed to how fast that specific signal type decays, not one blanket rule for every kind of event.

Can outreach be set up to fire automatically the moment a signal appears?

Detection can be automatic; sending should not be. The useful pattern is to have the system watch continuously and flag the account the moment a real signal appears, so nothing sits unnoticed for weeks, while a person still reviews and sends the actual message. That keeps the speed advantage of automated monitoring without losing the judgment a real outreach decision needs.

Related reading

Guides

Prioritizing accounts: fit and readiness

A practical account prioritization framework for life science sales teams: gate on fit first, then use buying-readiness signals to decide when to act inside your best-fit list.

Guides

Biotech and pharma buying signals

A working framework for life science buying signals: which events point to new budget or new work to outsource (funding, clinical and regulatory milestones, hiring, expansion), and which fill in the picture around them.

Reference

GTM signals glossary

Plain-language definitions of the fit, readiness, and buying-signal terms used in life science sales: from fit score and ICP to phase transitions, FDA milestones, and conference signals.

See it on your own market

Score the accounts you already have against your ICP.

Bring in the data you already work with, from your CRM or the providers you already use, and Arcova scores it against your ICP, watches for the life science signals that matter, and tells you who is ready for outreach and why.

Start for free
HomeResourcesArcova SignalsCompareHelp centerPrivacyTermsContact
© 2026 Arcova. All rights reserved.